questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-tyrosine kinases
Protein-tyrosine kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes",
"headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines et peptides de signalisation intracellulaire",
"url": "https://questionsmedicales.fr/mesh/D047908",
"about": {
"@type": "MedicalCondition",
"name": "Protéines et peptides de signalisation intracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D047908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agammaglobulinaemia tyrosine kinase",
"alternateName": "Agammaglobulinaemia Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D000077329",
"about": {
"@type": "MedicalCondition",
"name": "Agammaglobulinaemia tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000077329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Focal adhesion protein-tyrosine kinases",
"alternateName": "Focal Adhesion Protein-Tyrosine Kinases",
"url": "https://questionsmedicales.fr/mesh/D051416",
"about": {
"@type": "MedicalCondition",
"name": "Focal adhesion protein-tyrosine kinases",
"code": {
"@type": "MedicalCode",
"code": "D051416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.049"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinases",
"alternateName": "Janus Kinases",
"url": "https://questionsmedicales.fr/mesh/D053612",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D053612",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Janus kinase 1",
"alternateName": "Janus Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D053613",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D053613",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinase 3",
"alternateName": "Janus Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D053616",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D053616",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "TYK2 Kinase",
"alternateName": "TYK2 Kinase",
"url": "https://questionsmedicales.fr/mesh/D053634",
"about": {
"@type": "MedicalCondition",
"name": "TYK2 Kinase",
"code": {
"@type": "MedicalCode",
"code": "D053634",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase Kinases",
"alternateName": "Mitogen-Activated Protein Kinase Kinases",
"url": "https://questionsmedicales.fr/mesh/D020929",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase Kinases",
"code": {
"@type": "MedicalCode",
"code": "D020929",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 1",
"alternateName": "MAP Kinase Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D048369",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D048369",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 2",
"alternateName": "MAP Kinase Kinase 2",
"url": "https://questionsmedicales.fr/mesh/D048370",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 2",
"code": {
"@type": "MedicalCode",
"code": "D048370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 3",
"alternateName": "MAP Kinase Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D048371",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 4",
"alternateName": "MAP Kinase Kinase 4",
"url": "https://questionsmedicales.fr/mesh/D048670",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 4",
"code": {
"@type": "MedicalCode",
"code": "D048670",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 5",
"alternateName": "MAP Kinase Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D048671",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 5",
"code": {
"@type": "MedicalCode",
"code": "D048671",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 6",
"alternateName": "MAP Kinase Kinase 6",
"url": "https://questionsmedicales.fr/mesh/D048669",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 6",
"code": {
"@type": "MedicalCode",
"code": "D048669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 7",
"alternateName": "MAP Kinase Kinase 7",
"url": "https://questionsmedicales.fr/mesh/D048688",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 7",
"code": {
"@type": "MedicalCode",
"code": "D048688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syk kinase",
"alternateName": "Syk Kinase",
"url": "https://questionsmedicales.fr/mesh/D000072377",
"about": {
"@type": "MedicalCondition",
"name": "Syk kinase",
"code": {
"@type": "MedicalCode",
"code": "D000072377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "src-Family kinases",
"alternateName": "src-Family Kinases",
"url": "https://questionsmedicales.fr/mesh/D019061",
"about": {
"@type": "MedicalCondition",
"name": "src-Family kinases",
"code": {
"@type": "MedicalCode",
"code": "D019061",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "CSK tyrosine-protein kinase",
"alternateName": "CSK Tyrosine-Protein Kinase",
"url": "https://questionsmedicales.fr/mesh/D000081247",
"about": {
"@type": "MedicalCondition",
"name": "CSK tyrosine-protein kinase",
"code": {
"@type": "MedicalCode",
"code": "D000081247",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800.158"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "ZAP-70 Protein-tyrosine kinase",
"alternateName": "ZAP-70 Protein-Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D051746",
"about": {
"@type": "MedicalCondition",
"name": "ZAP-70 Protein-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D051746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases",
"alternateName": "Protein-Tyrosine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D011505",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Angela L Tyner",
"url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu."
}
},
{
"@type": "Person",
"name": "Eiji Kinoshita",
"url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Emiko Kinoshita-Kikuta",
"url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Tohru Koike",
"url": "https://questionsmedicales.fr/author/Tohru%20Koike",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Gongqin Sun",
"url": "https://questionsmedicales.fr/author/Gongqin%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities.",
"datePublished": "2022-08-04",
"url": "https://questionsmedicales.fr/article/37520798",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.hazadv.2022.100140"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.",
"datePublished": "2023-09-29",
"url": "https://questionsmedicales.fr/article/37783221",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2666-5247(23)00177-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36316084",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-061776"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-tyrosine kinases",
"item": "https://questionsmedicales.fr/mesh/D011505"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protein-tyrosine kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protein-tyrosine kinases",
"description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protein-tyrosine kinases",
"description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protein-tyrosine kinases",
"description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protein-tyrosine kinases",
"description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protein-tyrosine kinases",
"description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protein-tyrosine kinases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta&page=552#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une suractivité des kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de kinase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux cancers ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins préventifs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases à tyrosine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements sont courants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles des traitements supplémentaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases."
}
}
]
}
]
}
The coronavirus known as COVID-19, which causes pandemics, is causing a global epidemic at a critical stage today. Furthermore, novel mutations in the SARS-CoV-2 spike protein have been discovered in ...
This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise similar to AZD1222 (ChAdOx1 nCoV-1...
This phase 2/3, partly double-blinded, randomised, active-controlled study was done at 19 sites in the UK and four in Poland. Adult participants who had received a two-dose AZD1222 or mRNA vaccine pri...
Between June 27 and Sept 30, 2021, 1394 participants of the 1741 screened were randomly assigned to AZD1222 or AZD2816 following an AZD1222 (n=373, n=377) or mRNA vaccine (n=322, n=322) primary series...
Both boosters were well tolerated, with immunogenicity against ancestral SARS-CoV-2 similar to AZD1222 primary-series vaccination. AZD2816 gave greater immune responses against beta versus AZD1222....
AstraZeneca....
Type 1 diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing beta cells resulting in insulin deficiency and hyperglycaemic. Today, no approved therapy exists to h...
Individuals ≥12 and <29 years recently diagnosed with T1D (<6 months) will be screened for the HLA DR3-DQ2 haplotype, endogenous insulin production estimated by fasting C-peptide and presence of GAD65...
The trial is approved by Ethics Committees in Poland (124/2021), the Netherlands (R21.089), Sweden (2021-05063), Czech Republic (EK-1144/21), Germany (2021361) and Spain (21/2021). Results will be pub...
EudraCT identifier: 2021-002731-32, NCT identifier: NCT05018585....